查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1243266

胃輕癱治療藥的全球市場

Gastroparesis Drugs
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

胃輕癱治療藥的全球市場2030年前將達到95億美元

在COVID-19後改變的商務環境中，2022年66億美元的胃輕癱治療藥的全球市場，2030年前將達到95億美元的規模，在2022年～2030年預計將以年複合成長率4.7％增長。本報告所分析之市場區隔之一的特發性胃不全症將記錄年複合成長率5.7％，到分析期間結束時達到39億美元。糖尿病性胃不全症，考慮疫情後的復甦，今後8年的年複合成長率將修正為4.7％。

美國市場估算為20億美元美元，中國則將以年複合成長率4.4％的速度成長。

美國的胃輕癱治療藥市場在2022年估算為20億美元。作為世界第2大經濟大國的中國，在2022年～2030年年複合成長率預計將為4.4％，2030年前將達到17億美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年～2030年預計將各以4.5％和3.9％的速度成長。在歐洲市場中，德國將以年複合成長率約4.5％成長。

調查對像企業範例

  • Abbott Laboratories
  • Allergan PLC
  • AstraZeneca PLC
  • Cadila Pharmaceuticals Ltd.
  • ETX Pharma, Inc.
  • Evoke Pharma, Inc.
  • GlaxoSmithKline PLC
  • Neurogastrx Inc.
  • Theravance Biopharma, Inc.
  • Valeant Pharmaceuticals International, Inc.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 全球其他地區

第4章 競爭

簡介目錄
Product Code: MCP12146

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Gastroparesis Drugs Market to Reach $9.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Gastroparesis Drugs estimated at US$6.6 Billion in the year 2022, is projected to reach a revised size of US$9.5 Billion by 2030, growing at aCAGR of 4.7% over the period 2022-2030. Idiopathic Gastroparesis, one of the segments analyzed in the report, is projected to record 5.7% CAGR and reach US$3.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Diabetic Gastroparesis segment is readjusted to a revised 4.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 4.4% CAGR

The Gastroparesis Drugs market in the U.S. is estimated at US$2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 4.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 3.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Select Competitors (Total 47 Featured) -

  • Abbott Laboratories
  • Allergan PLC
  • AstraZeneca PLC
  • Cadila Pharmaceuticals Ltd.
  • ETX Pharma, Inc.
  • Evoke Pharma, Inc.
  • GlaxoSmithKline PLC
  • Neurogastrx Inc.
  • Theravance Biopharma, Inc.
  • Valeant Pharmaceuticals International, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Gastroparesis Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Gastroparesis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Gastroparesis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Gastroparesis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Diabetic Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Diabetic Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Diabetic Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Idiopathic Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Idiopathic Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Idiopathic Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Post-Surgical Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Post-Surgical Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Post-Surgical Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 16: World Gastroparesis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for eCommerce by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for eCommerce by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: World 16-Year Perspective for eCommerce by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gastroparesis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • JAPAN
    • Gastroparesis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • CHINA
    • Gastroparesis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: China 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: China 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • EUROPE
    • Gastroparesis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Gastroparesis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Gastroparesis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Gastroparesis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • FRANCE
    • Gastroparesis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: France 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: France 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • GERMANY
    • Gastroparesis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Gastroparesis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Gastroparesis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Gastroparesis Drugs by Disease Type - Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Gastroparesis Drugs by Disease Type - Percentage Breakdown of Value Sales for Idiopathic Gastroparesis, Diabetic Gastroparesis, Post-Surgical Gastroparesis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Gastroparesis Drugs by Distribution Channel - Pharmacies, Hospitals, Clinics and eCommerce Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Rest of World 16-Year Perspective for Gastroparesis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Pharmacies, Hospitals, Clinics and eCommerce for the Years 2014, 2023 & 2030

IV. COMPETITION